Castle Biosciences - CSTL Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CSTL shares.
View CSTL analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued 1 year price objectives for Castle Biosciences' shares. Their CSTL share price forecasts range from $38.00 to $80.00. On average, they anticipate the company's share price to reach $52.00 in the next year. This suggests a possible upside of 133.8% from the stock's current price.
View analysts price targets for CSTL or view top-rated stocks among Wall Street analysts.

Castle Biosciences' stock was trading at $23.54 on January 1st, 2023. Since then, CSTL shares have decreased by 5.5% and is now trading at $22.24.
View the best growth stocks for 2023 here.

Castle Biosciences saw a drop in short interest in the month of February. As of February 28th, there was short interest totaling 862,000 shares, a drop of 25.0% from the February 13th total of 1,150,000 shares. Based on an average daily volume of 154,900 shares, the short-interest ratio is presently 5.6 days.
View Castle Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our CSTL earnings forecast.

Castle Biosciences, Inc. (NASDAQ:CSTL) posted its earnings results on Sunday, November, 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.13. The firm had revenue of $23.48 million for the quarter, compared to the consensus estimate of $23.66 million. Castle Biosciences had a negative trailing twelve-month return on equity of 15.45% and a negative net margin of 48.99%. During the same period last year, the firm posted ($0.23) earnings per share.

ETFs with the largest weight of Castle Biosciences (NASDAQ:CSTL) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), First Trust Innovation Leaders ETF (ILDR), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), iShares U.S. Healthcare Providers ETF (IHF), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB).

Castle Biosciences issued an update on its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $170.00 million-$180.00 million, compared to the consensus revenue estimate of $168.34 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC).

(CSTL) raised $50 million in an IPO on Thursday, July 25th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. SVB Leerink and Baird served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Castle Biosciences trades on the NASDAQ under the ticker symbol "CSTL."

Castle Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Granahan Investment Management LLC (3.96%), Millennium Management LLC (3.47%), Principal Financial Group Inc. (3.46%), Kornitzer Capital Management Inc. KS (2.72%), Portolan Capital Management LLC (2.22%) and Palisade Capital Management LLC NJ (2.09%). Insiders that own company stock include Adam Jay Sussman, Bernhard E Spiess, Bernhard E Spiess, Bonnie H Anderson, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Derek J Maetzold, Frank Stokes, Jeffrey E Eberwein, Joseph C Cook III, Kristen M Oelschlager, Mara G Aspinall, Sofinnova Healthquest Partners, Tiffany Olson and Tobin W Juvenal.
View institutional ownership trends.

Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CSTL stock can currently be purchased for approximately $22.24.

Castle Biosciences (NASDAQ:CSTL) has a market capitalization of $591.14 million and generates $137.04 million in revenue each year. The company earns $-67,140,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis.

The company employs 342 workers across the globe.

Castle Biosciences' mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The official website for the company is castlebiosciences.com. The company can be reached via phone at (866) 788-9007 or via email at ir@castlebiosciences.com.